143 related articles for article (PubMed ID: 35738853)
1. A Role for Ranolazine in the Treatment of Ventricular Arrhythmias?
Andrade JG; Deyell MW
JACC Clin Electrophysiol; 2022 Jun; 8(6):763-765. PubMed ID: 35738853
[No Abstract] [Full Text] [Related]
2. Ranolazine therapy in drug-refractory ventricular arrhythmias.
Curnis A; Salghetti F; Cerini M; Vizzardi E; Sciatti E; Vassanelli F; Villa C; Inama L; Raweh A; Giacopelli D; Bontempi L
J Cardiovasc Med (Hagerstown); 2017 Jul; 18(7):534-538. PubMed ID: 28368882
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
Zareba W; Daubert JP; Beck CA; Huang DT; Alexis JD; Brown MW; Pyykkonen K; McNitt S; Oakes D; Feng C; Aktas MK; Ayala-Parades F; Baranchuk A; Dubuc M; Haigney M; Mazur A; McPherson CA; Mitchell LB; Natale A; Piccini JP; Raitt M; Rashtian MY; Schuger C; Winters S; Worley SJ; Ziv O; Moss AJ;
J Am Coll Cardiol; 2018 Aug; 72(6):636-645. PubMed ID: 30071993
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine in Cardiac Arrhythmia.
Saad M; Mahmoud A; Elgendy IY; Richard Conti C
Clin Cardiol; 2016 Mar; 39(3):170-8. PubMed ID: 26459200
[TBL] [Abstract][Full Text] [Related]
5. Ranolazine: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias.
Shenasa M; Assadi H; Heidary S; Shenasa H
Card Electrophysiol Clin; 2016 Jun; 8(2):467-79. PubMed ID: 27261835
[TBL] [Abstract][Full Text] [Related]
6. Ranolazine for the suppression of ventricular arrhythmia: a case series.
Yeung E; Krantz MJ; Schuller JL; Dale RA; Haigney MC
Ann Noninvasive Electrocardiol; 2014 Jul; 19(4):345-50. PubMed ID: 24533675
[TBL] [Abstract][Full Text] [Related]
7. Ranolazine and its Antiarrhythmic Actions.
Polytarchou K; Manolis AS
Cardiovasc Hematol Agents Med Chem; 2015; 13(1):31-9. PubMed ID: 26245658
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
Roses-Noguer F; Jarman JW; Clague JR; Till J
Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
[TBL] [Abstract][Full Text] [Related]
9. Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions.
Gojkovic O; Aliot EM; Capucci A; Connolly SJ; Crijns H; Hohnloser SH; Kulakowski P; Roy D; Radzik D; Singh BN; Kowey PR
Heart Rhythm; 2012 Feb; 9(2):217-224.e2. PubMed ID: 21978965
[TBL] [Abstract][Full Text] [Related]
10. Antiarrhythmic properties of ranolazine--from bench to bedside.
Tzeis S; Andrikopoulos G
Expert Opin Investig Drugs; 2012 Nov; 21(11):1733-41. PubMed ID: 22916846
[TBL] [Abstract][Full Text] [Related]
11. Importance of the atrial channel for ventricular arrhythmia therapy in the dual chamber implantable cardioverter defibrillator.
Dijkman B; Wellens HJ
J Cardiovasc Electrophysiol; 2000 Dec; 11(12):1309-19. PubMed ID: 11196552
[TBL] [Abstract][Full Text] [Related]
12. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
Bunch TJ; Mahapatra S; Murdock D; Molden J; Weiss JP; May HT; Bair TL; Mader KM; Crandall BG; Day JD; Osborn JS; Muhlestein JB; Lappe DL; Anderson JL
Pacing Clin Electrophysiol; 2011 Dec; 34(12):1600-6. PubMed ID: 21895727
[TBL] [Abstract][Full Text] [Related]
13. Relation of T-wave alternans to mortality and nonsustained ventricular tachycardia in patients with non-ST-segment elevation acute coronary syndrome from the MERLIN-TIMI 36 trial of ranolazine versus placebo.
Nieminen T; Scirica BM; Pegler JR; Tavares C; Pagotto VP; Kanas AF; Sobrado MF; Nearing BD; Umez-Eronini AA; Morrow DA; Belardinelli L; Verrier RL
Am J Cardiol; 2014 Jul; 114(1):17-23. PubMed ID: 24852915
[TBL] [Abstract][Full Text] [Related]
14. Ranolazine Therapy in Cardiac Arrhythmias.
Pulford BR; Kluger J
Pacing Clin Electrophysiol; 2016 Sep; 39(9):1006-15. PubMed ID: 27358212
[TBL] [Abstract][Full Text] [Related]
15. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
[TBL] [Abstract][Full Text] [Related]
16. Implantable cardioverter defibrillator prevents sudden cardiac death in systemic sclerosis.
Bernardo P; Conforti ML; Bellando-Randone S; Pieragnoli P; Blagojevic J; Kaloudi O; Guiducci S; Porta F; Padeletti L; Gensini GF; Matucci-Cerinic M
J Rheumatol; 2011 Aug; 38(8):1617-21. PubMed ID: 21632680
[TBL] [Abstract][Full Text] [Related]
17. Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia.
Pokorney SD; Mi X; Hammill BG; Allen LaPointe NM; Curtis LH; Al-Khatib SM
Am J Cardiol; 2017 May; 119(9):1401-1406. PubMed ID: 28341360
[TBL] [Abstract][Full Text] [Related]
18. Ranolazine in Patients With Implantable Cardioverter-Defibrillators: Ready for Prime Time?
Albert CM
J Am Coll Cardiol; 2018 Aug; 72(6):646-649. PubMed ID: 30071994
[No Abstract] [Full Text] [Related]
19. Approach to reduction of ventricular arrhythmias and implantable cardioverter-defibrillator therapies in patients with heart failure.
Sengupta J; Abdelhadi R
Curr Opin Cardiol; 2013 May; 28(3):337-43. PubMed ID: 23549236
[TBL] [Abstract][Full Text] [Related]
20. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.
Powell BD; Saxon LA; Boehmer JP; Day JD; Gilliam FR; Heidenreich PA; Jones PW; Rousseau MJ; Hayes DL
J Am Coll Cardiol; 2013 Oct; 62(18):1674-1679. PubMed ID: 23810882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
